Factors influencing the profitability of pharmaceutical research

R and D Management

Volumn 38, Issue 2, 2008, Pages 221-230

  Charalambous, Charis ^a   Gittins, John ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 39449083839     PISSN: 00336807     EISSN: 14679310     Source Type: Journal    
DOI: 10.1111/j.1467-9310.2008.00507.x     Document Type: Article

References (20)

1. Bergman, S.W. Gittins, J.C. (1985) Statistical Methods for Pharmaceutical Research Planning. New York : Marcel Dekker.
2. Black, F. Scholes, M. (1973) The pricing of options and corporate liabilities. Journal of Political Economics, 81, 637 659.
3. Boschi, R.A.A. (1982) Modelling exploratory research. European Journal of Operational Research, 10, 250 259.
4. Brealey, R.A. Myers, S.C. (2000) Principles of Corporate Finance, 6th ed. New York : McGraw Hill.
5. Charalambous, C. (2006). Optimal selection policy for a sequence of candidate drugs. Doctorate thesis transfer of status report, Department of Statistics, University of Oxford.
6. Chen, B.P.K. (2004). Prioritization of research projects in the pharmaceutical industry. Doctoral thesis, Department of Statistics, University of Oxford.
7. Comanor, W.S. (1986) The political economy of the pharmaceutical industry. Journal of Economic Literature, 24, 3, 1178 1217.
8. Doraszelski, U. (2001) The net present value method versus the option value of waiting: A note on Farzin, Huisman and Kort (1998). Journal of Economic Dynamics and Control, 25, 8, 1109 1115.
9. Gittins, J.C. (1996) Quantitative methods in the planning of pharmaceutical research. Drug Information Journal, 30, 479 487.
10. Gittins, J.C. (1997a) Why crash pharmaceutical research? R&D Management, 27, 79 85.
11. Gittins, J.C. (1997b) Algorithms for allocating resources to multi-stage pharmaceutical research projects. In Christer, A.H., Osaki, S. Thomas, L.C. (eds.), Stochastic Modelling in Innovative Manufacturing. Lecture Notes in Economics and Mathematical Systems Series, No. 445. Berlin : Springer, pp. 123 139.
12. Grabowski, H. (1991) Pharmaceutical R&D: Returns and Risk. London : Centre of Medicines Research Annual Lecture, CMR.
13. Gray, N. (2005). PharmExec 50: our sixth annual report of the world's top 50 pharma companies, special report.
14. Information Centre, Royal Pharmaceutical Society 2007). Mergers and takeovers within the pharmaceutical industry.
15. Jacob, W. Kwak, Y.H. (2003) In search of innovative techniques to evaluate pharmaceutical R&D projects. Technovation, 23, 4, 291 296.
16. Miller, P. (2005) Role of pharmaeconomic analysis in R&D decision making. Pharmacoeconomics, 23, 1 12.
17. Poh, K.L., Ang, B.W. Bai, F. (2001) A comparative analysis of R&D project evaluation methods. R&D Management, 31, 63 75.
18. Spilker, B. (1989) Multinational Drug Companies-Issues in Drug Discovery and Development. New York : Raven Press.
19. Yu, J.-Y. (2007). Models and software for improving the profitability of pharmaceutical research. Doctoral thesis, Department of Statistics, University of Oxford.
20. Yu, J.-Y. Gittins, J.C. (2008) Models and software for improving the profitability of pharmaceutical research. European Journal of Operational Research (in press).